166 related articles for article (PubMed ID: 31100506)
1. Drug susceptibility profile of Mycobacterium kansasii clinical isolates from Brazil.
de Carvalho LD; de Queiroz Mello FC; Redner P; Campos CED; de Souza Caldas PC; da Silva Lourenço MC; Ramos JP
J Glob Antimicrob Resist; 2019 Dec; 19():228-230. PubMed ID: 31100506
[TBL] [Abstract][Full Text] [Related]
2. Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates.
da Silva Telles MA; Chimara E; Ferrazoli L; Riley LW
J Med Microbiol; 2005 Oct; 54(Pt 10):975-979. PubMed ID: 16157553
[TBL] [Abstract][Full Text] [Related]
3. Clinical and Microbiological Characteristics of Mycobacterium kansasii Pulmonary Infections in China.
Guo Y; Cao Y; Liu H; Yang J; Wang W; Wang B; Li M; Yu F
Microbiol Spectr; 2022 Feb; 10(1):e0147521. PubMed ID: 35019778
[TBL] [Abstract][Full Text] [Related]
4. Drug Susceptibility Profiling and Genetic Determinants of Drug Resistance in Mycobacterium kansasii.
Bakuła Z; Modrzejewska M; Pennings L; Proboszcz M; Safianowska A; Bielecki J; van Ingen J; Jagielski T
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437627
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial susceptibility and minimum inhibitory concentration distribution of common clinically relevant non-tuberculous mycobacterial isolates from the respiratory tract.
He G; Wu L; Zheng Q; Jiang X
Ann Med; 2022 Dec; 54(1):2500-2510. PubMed ID: 36120867
[No Abstract] [Full Text] [Related]
6. Drug resistance profile of Mycobacterium kansasii clinical isolates before and after 2-month empirical antimycobacterial treatment.
Zhang Y; Yu C; Jiang Y; Zheng X; Wang L; Li J; Shen X; Xu B
Clin Microbiol Infect; 2023 Mar; 29(3):353-359. PubMed ID: 36209990
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Antimicrobial Susceptibility of Nontuberculous Mycobacteria in Iran.
Heidarieh P; Mirsaeidi M; Hashemzadeh M; Feizabadi MM; Bostanabad SZ; Nobar MG; Hashemi Shahraki A
Microb Drug Resist; 2016 Mar; 22(2):172-8. PubMed ID: 26468990
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii.
Guna R; Muñoz C; Domínguez V; García-García A; Gálvez J; de Julián-Ortiz JV; Borrás R
J Antimicrob Chemother; 2005 Jun; 55(6):950-3. PubMed ID: 15824090
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activities of linezolid, telithromycin, clarithromycin, levofloxacin, moxifloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii.
Alcaide F; Calatayud L; Santín M; Martín R
Antimicrob Agents Chemother; 2004 Dec; 48(12):4562-5. PubMed ID: 15561826
[TBL] [Abstract][Full Text] [Related]
10. [Antimycobacterial susceptibility against nontuberculous mycobacteria using brothmic NTM].
Kawata N; Kawahara S; Tada A; Takigawa N; Shibayama T; Soda R; Takahashi K
Kekkaku; 2006 Apr; 81(4):329-35. PubMed ID: 16715941
[TBL] [Abstract][Full Text] [Related]
11. Drug susceptibility testing of slowly growing non-tuberculous mycobacteria using slomyco test-system.
Litvinov V; Makarova M; Galkina K; Khachaturiants E; Krasnova M; Guntupova L; Safonova S
PLoS One; 2018; 13(9):e0203108. PubMed ID: 30222736
[TBL] [Abstract][Full Text] [Related]
12. Short communication: subtyping of Mycobacterium kansasii by PCR-restriction enzyme analysis of the hsp65 gene.
Bakuła Z; Safianowska A; Nowacka-Mazurek M; Bielecki J; Jagielski T
Biomed Res Int; 2013; 2013():178725. PubMed ID: 24455675
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial resistance in Mycobacterium abscessus complex isolated from patients with skin and soft tissue infections at a tertiary teaching hospital in Taiwan.
Lee MC; Sun PL; Wu TL; Wang LH; Yang CH; Chung WH; Kuo AJ; Liu TP; Lu JJ; Chiu CH; Lai HC; Chen NY; Yang JH; Wu TS
J Antimicrob Chemother; 2017 Oct; 72(10):2782-2786. PubMed ID: 29091186
[TBL] [Abstract][Full Text] [Related]
14. AIDS-related Mycobacterium kansasii infection with initial resistance to clarithromycin.
Burman WJ; Stone BL; Brown BA; Wallace RJ; Böttger EC
Diagn Microbiol Infect Dis; 1998 Jun; 31(2):369-71. PubMed ID: 9635911
[TBL] [Abstract][Full Text] [Related]
15. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome.
Shitrit D; Baum GL; Priess R; Lavy A; Shitrit AB; Raz M; Shlomi D; Daniele B; Kramer MR
Chest; 2006 Mar; 129(3):771-6. PubMed ID: 16537880
[TBL] [Abstract][Full Text] [Related]
16. [Frequently Isolated Slow Growing Nontuberculous Mycobacteria from Pulmonary Samples and Evaluation of Drug Susceptibility Testing Results in a Referral Hospital in Turkey].
Ceyhan İ; Özkara Ş; Güler MZ; Dulkar G; Altınsoy R; Vezir S
Mikrobiyol Bul; 2019 Jul; 53(3):330-335. PubMed ID: 31414634
[TBL] [Abstract][Full Text] [Related]
17. Species identification of Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii using rpoB and hsp65, and susceptibility testing to eight antibiotics.
Nie W; Duan H; Huang H; Lu Y; Bi D; Chu N
Int J Infect Dis; 2014 Aug; 25():170-4. PubMed ID: 24932856
[TBL] [Abstract][Full Text] [Related]
18. Outbreaks due to Mycobacterium abscessus subsp. bolletii in southern Brazil: persistence of a single clone from 2007 to 2011.
Nunes LS; Baethgen LF; Ribeiro MO; Cardoso CM; de Paris F; De David SMM; da Silva MG; Duarte RS; Barth AL
J Med Microbiol; 2014 Oct; 63(Pt 10):1288-1293. PubMed ID: 25038135
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibility of Mycobacterium kansasii to the difluorinated quinolone sparfloxacin using a broth microdilution and macrodilution MIC system.
Royo P; Martín-Casabona N; Martínez E; Andonegui M
Int J Tuberc Lung Dis; 1999 Apr; 3(4):349-53. PubMed ID: 10206507
[TBL] [Abstract][Full Text] [Related]
20. [Clinical characteristics and drug susceptibility test of nontuberculous mycobacterial lung disease].
Lou H; Sun Q; Gu J; Yang H; Hao XH; Xiao HP; Sha W
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Dec; 42(12):901-906. PubMed ID: 31826533
[No Abstract] [Full Text] [Related]
[Next] [New Search]
